Dr. Michael Glickman

Researchers from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center are expanding the understanding of how the BCG treatment for early bladder cancer works.

Weill Cornell Medicine has been awarded a five-year, $5 million grant from the National Institutes of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health to establish a new multi-institutional center for tuberculosis (TB) research and training the next generation of TB investigators.

Tuberculosis (TB) is a wily old killer, one of the deadliest infectious diseases in history and one of the few that naturally infects only humans.

Gut bacteria play an important role in the body’s response to treatment for tuberculosis (TB), according to researchers at Weill Cornell Medicine and Memorial Sloan Kettering.